| | | | |

Boosting Mesothelioma Survival with VEGF-Inhibitor

ByAlex Strauss

The VEGF inhibitor cediranib may not yet be out of the running as a mesothelioma treatment.

Although previous studies have found it to have dose-limiting side effects, a new study in the Journal of Thoracic Oncology finds that, at the right dose, it could boost the effectiveness of standard mesothelioma chemotherapy.

What is Cediranib?

Cediranib, an oral drug made by Astra Zeneca, is a powerful inhibitor of vascular endothelial growth factor (VEGF), a signal protein that can stimulate the growth of cancer cells.

Research has found that mesothelioma patients who have higher serum levels of VEGF have a lower chance of survival. Cediranib has the ability to counter the effects of VEGF by latching onto VEGF receptor sites inside cancer cells, preventing the protein from having an effect on those cells.

Cediranib in Mesothelioma Treatment

In 2011, an NIH study found that cediranib could significantly shrink tumors in people with alveolar soft part sarcoma, a rare malignancy for which no other chemotherapy drugs had been effective. But a 2012 study of cediranib in mesothelioma patients found that most could not tolerate the drug at doses higher than 45 milligrams and many still had serious side effects like hypertension and blood clots at 30 milligrams.

For the new Phase I trial, mesothelioma researchers cut the dose in half and combined it with standard chemotherapy. In this study, most pleural mesothelioma patients who received 20 milligrams of cediranib along with pemetrexed and cisplatin did not experience side effects that were serious enough to stop the study.

The mesothelioma patients selected for the study had been deemed inoperable and had not yet received any chemotherapy. They were treated with 6 cycles of chemotherapy along with cediranib.

Although some did experience a drop in white blood cells, gastrointestinal upset, and low blood platelets, at six weeks, the disease control rate was 90 percent. The median overall survival for patients on this regimen was 16.2 months.

“Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy,” writes oncologist Anne Tsao, MD, of MD Anderson Cancer Center in Texas.

Next Steps for Cediranib

The next step for the supplemental use of cediranib in the chemotherapeutic treatment of malignant mesothelioma is to test the combination in a planned Phase II trial. Phase I clinical trials establish dose and safety while Phase II trials focus on a drug’s effectiveness.

Although most mesothelioma patients receive chemotherapy as part of their treatment, it is only moderately effective. Even with the gold standard chemotherapy regimen of pemetrexed and cisplatin, mesothelioma is usually fatal within a year.

A number of new and ongoing mesothelioma studies are focused on potential methods for boosting the power of chemotherapy.

Sources:

Tsao, AS, et al, “Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)”, June 6, 2017, Journal of Thoracic Oncology, Epub ahead of print

Campbell, NP et al, “Cediranib in Patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium”, July 23, 2012, Lung Cancer, Epub ahead of print

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…